alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. International journal of geriatric psychiatry 2004-06 Treatments

    The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs.

  2. Pharmacologic treatments of dementia

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Medical clinics of North America 2002-05 Treatments

    This standard is based on the results of large-scale, double-blind, placebo-controlled trials.

  3. Nefiracetam. Daiichi Seiyaku

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Current opinion in investigational drugs (London, England : 2000) 2002-05 Clinical trials

    Nefiracetam (DM-9384) is a cerebral metabolic product under development by Daiichi for the potential treatment of the after-effects of cerebrovascular disorders.

  4. Donepezil in the treatment of patients with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert review of neurotherapeutics 2001-09 Treatments

    Donepezil is the most widely used acetylcholinesterase inhibitor licensed for symptomatic treatment of mild-to-moderate Alzheimer's disease.

  5. Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. PharmacoEconomics 2001 Clinical trials

    Faced with increasing demands on demonstrating cost effectiveness, pharmaceutical companies are required to conduct pharmacoeconomic evaluations throughout the drug development programme.

  6. Late life depression

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. European archives of psychiatry and clinical neuroscience 2001 Risk factors

    Depression has an overall prevalence of 5-8%.

  7. Clinical experience with Cerebrolysin

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of neural transmission. Supplementum 2000 Clinical trials

    Cerebrolysin is a peptidergic drug which displays neurotrophic action in various animal models.

  8. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert opinion on investigational drugs 1999-10 Treatments

    Alzheimer's disease is, in part, characterised by the loss of neurones in the basal forebrain cholinergic cells that project to the cerebral cortex and hippocampus.

  9. [Sleep disorders and dementia]

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Praxis 1997-08-27 Risk factors

    A clinically relevant sleep-wake disturbance is found in up to half the patients with dementia, and the sundowning agitation is a common cause of institutionalisation of demented geriatric patients.

  10. Dementia: A Clinical Approach

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Annals of Internal Medicine 1992-08-15 Lewy body dementia

    1. Dementia: Significance, Definition, and Epidemiology 2.

  11. Dementia Praecox and Paraphrenia

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Annals of Internal Medicine 1972-06-01 Risk factors

    The German psychiatrist Emil Kraepelin (1856 - 1926) is justly called father of modern psychiatry.

  12. Therapeutic strategies for Alzheimer's disease in clinical trials

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacological reports : PR 2015-08-05 Treatments

    Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an incurable, progressive neurodegenerative disorder.

  13. Second-Generation Antipsychotics and Tardive Syndromes in Affective Illness: A Public Health Problem With Neuropsychiatric Consequences

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. American Journal of Public Health 2015-02 Clinical safety

    Food and Drug Administration–approved information and public advertisements belie neurodegenerative risks for second-generation antipsychotics in affective illness.

  14. Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer's Research & Therapy 2015-01-29 Clinical safety

    Neuropsychiatric symptoms of Alzheimer’s disease (NPS-AD) are highly prevalent and lead to poor medical and functional outcomes.

  15. New developments of clinical trial in immunotherapy for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current pharmaceutical biotechnology 2015-01-01 Treatments

    Active or passive immunotherapy is expected to slow or stop the pathological process of Alzheimer's disease (AD).

  16. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert opinion on drug safety 2014-06-01 Treatments

    Patients diagnosed with AD still mostly benefit from four compounds to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period.

  17. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert opinion on biological therapy 2013-04-10 Treatments

    Expert opinion Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).

  18. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The primary care companion for CNS disorders 2013-03-07 Treatments

    AChE-selective inhibitors and a dual AChE and BuChE inhibitor demonstrate symptomatic efficacy in AD.

  19. A review on cholinesterase inhibitors for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Archives of pharmacal research 2013-02-24 Treatments

    Alzheimer's disease (AD), a progressive neurodegenerative disorder, is characterized by the deficits in the cholinergic system and deposition of beta amyloid (Aβ) in the form of neurofibrillary tangles and amyloid plaques.

  20. Discovering new treatments for Alzheimer's disease by repurposing approved medications

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current topics in medicinal chemistry 2013-01-01 Drug development

    Alzheimer's disease (AD) is the most common cause of dementia and a major cause of morbidity and mortality.

  21. Current and future treatments for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Therapeutic advances in neurological disorders 2013-01-01 Treatments

    Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations.

  22. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current Alzheimer research 2012-07-01 Treatments

    Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for moderate to severe Alzheimer's disease (AD) treatment within the U.S. and Europe under brand name Namenda (Forest), Axura and Akatinol (Merz), and Ebixa and Abixa (Lundbeck), may have potential in alleviating additional neurological conditions, such as vascular dementia (VD) and Parkinson's disease (PD).

  23. Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2012-06-23 Digital health tools

    A condition of excess activity in the hippocampal formation is observed in the aging brain and in conditions that confer additional risk during aging for Alzheimer's disease.

  24. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. British journal of clinical pharmacology 2012-04-01 Treatments

    Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine.

  25. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2011-11-15 Treatments

    A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized.

From across this topic

10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics